Professor, Internal Medicine, University of Michigan Medical School
Cardiology
Dr. Vallerie V. McLaughlin, MD
|
|
Give Review
Vallerie V. McLaughlin, MD works in the field of Cardiology. She went to medical school at Northwestern University Feinberg School of Medicine. Northwestern University Feinberg School of Medicine is ranked 19 in research and 29 in primary care medicine She received awards:"Regional Top Doctor", "CMS Meaningful Use Stage 1 Certification" and "Fellow (FACC)". Doctor Vallerie V. McLaughlin, MD is a published doctor. She has 90 papers published. The most current publication "The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension." Dr. Vallerie V. McLaughlin accepts Medicare payments and is registered with Medicare.gov.
Publications
- Screening and Early Detection of Pulmonary Arterial Hypertension in Connective Tissue Diseases. It Is Time to Institute It!
- New horizons in Pulmonary arterial hypertension management.
- Evidence-based detection of Pulmonary arterial hypertension in systemic sclerosis: the DETECT study.
- Two formulations of epoprostenol sodium in the treatment of Pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in Pulmonary arterial hypertension),...
- Treatment goals of Pulmonary hypertension.
- Recognition of Pulmonary hypertension in the rheumatology community: lessons from a Quality Enhancement Research Initiative.
- A paradigm shift in Pulmonary arterial hypertension management.
- Parenteral and inhaled prostanoid therapy in the treatment of Pulmonary arterial hypertension.
- Screening and diagnostic modalities for connective tissue Disease-associated pulmonary arterial hypertension: A systematic review.
- Recommendations for screening and detection of connective-tissue Disease associated pulmonary arterial hypertension.
- One-year experience with intravenous treprostinil for Pulmonary arterial hypertension.
- Referral of patients with Pulmonary hypertension diagnoses to tertiary Pulmonary hypertension centers: the multicenter RePHerral study.
- Managing pulmonary arterial hypertension and optimizing treatment options: prognosis of pulmonary Artery hypertension.
- Contemporary trends in the diagnosis and management of Pulmonary arterial hypertension: an initiative to close the care gap.
- Increased CD39 Nucleotidase Activity on Microparticles from Patients with Idiopathic Pulmonary Arterial Hypertension.
- Long-term effects of inhaled treprostinil in patients with Pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arte...
- Does the Outcome Justify an Oral-First Treatment Strategy for Management of Pulmonary Arterial Hypertension?
- Prognosis of pulmonary arterial hypertension: the power of clinical registries of rare Diseases.
- Addition of inhaled treprostinil to oral therapy for Pulmonary arterial hypertension: a randomized controlled clinical trial.
- Updated evidence-based treatment algorithm in Pulmonary arterial hypertension.
- End points and clinical trial design in Pulmonary arterial hypertension.
- The 4th World Symposium on Pulmonary Hypertension. Introduction.
- Ambrisentan therapy in patients with Pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.
- Pulmonary Diseases and the heart.
- Transition from IV epoprostenol to subcutaneous treprostinil in Pulmonary arterial hypertension: a controlled trial.
- Creation of a model comparing 6-minute walk test to metabolic equivalent in evaluating treatment effects in Pulmonary arterial hypertension.
- Sickle cell Disease-associated pulmonary hypertension: a coat of many colors.
- Medical therapy for Pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.
- Randomized study of adding inhaled iloprost to existing bosentan in Pulmonary arterial hypertension.
- Safety and efficacy of IV treprostinil for Pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial.
- Transition from intravenous epoprostenol to intravenous treprostinil in Pulmonary hypertension.
- Pulmonary Arterial Hypertension: New Management Options.
- Elevated basic fibroblast growth factor levels in patients with Pulmonary arterial hypertension.
- Classification and epidemiology of Pulmonary hypertension.
- Clinical and angiographic profile of patients with markedly elevated Coronary calcium scores (>or=1000) detected by electron beam computed tomography.
- Endothelin receptor blockers in cardiovascular Disease.
- Successful management of pregnancy in a patient with eisenmenger Syndrome with epoprostenol.
- Survival in primary Pulmonary hypertension: the impact of epoprostenol therapy.
- Detection of subclinical cardiovascular Disease: the emerging role of electron beam computed tomography.
- Invasive Streptococcus pneumoniae in Perth teaching hospitals, 1990 to 1994.
- Cardiac complications of systemic sclerosis.
- Looking to the future: a new decade of Pulmonary arterial hypertension therapy.
- The 6-min walk test (6MW) as an efficacy endpoint in Pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect.
- Molecular and functional analysis identifies ALK-1 as the predominant cause of Pulmonary hypertension related to hereditary haemorrhagic telangiectasia.
- Severe Pulmonary hypertension: critical care clinics.
- Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of Disease. A randomized, controlled trial.
- Survival in patients with class III idiopathic Pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients sta...
- Survival in patients with Pulmonary arterial hypertension treated with first-line bosentan.
- Severe Pulmonary hypertension associated with COPD.
- Lung transplantation for Pulmonary hypertension: patient selection and maintenance therapy while awaiting transplantation.
- Relation between hormone replacement therapy in women and Coronary artery disease estimated by electron beam tomography.
- Medical & surgical approaches to Pulmonary hypertension.
- Compassionate use of continuous prostacyclin in the management of secondary Pulmonary hypertension: a case series.
- Reduction in Pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary Pulmonary hypertension.
- Delivery of intravenous treprostinil at low infusion rates using a miniaturized infusion pump in patients with Pulmonary arterial hypertension.
- Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.
- Survival with first-line bosentan in patients with primary Pulmonary hypertension.
- Pulmonary hypertension--advances in medical and surgical interventions.
- The effects of Chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension.
- Usefulness of Atrial septostomy as a treatment for primary pulmonary hypertension and guidelines for its application.
- Stenting to reverse left ventricular ischemia due to left main Coronary artery compression in primary pulmonary hypertension.
- Development of nonspecific interstitial pneumonitis associated with long-term treatment of primary Pulmonary hypertension with prostacyclin.
- The short-term effects of digoxin in patients with right ventricular dysfunction from Pulmonary hypertension.
- Utility of electron beam computed tomography to stratify patients presenting to the emergency room with chest pain.
- Depressive symptoms in Pulmonary arterial hypertension: prevalence and association with functional status.
- Opportunities and challenges in the study of Pulmonary arterial hypertension.
- Acute right ventricular failure in the setting of Acute pulmonary embolism or chronic pulmonary hypertension: a detailed review of the pathophysiology, diagnosis, and ...
- The metabolic Syndrome and pulmonary vascular disease.
- Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion.
- Complications of right heart catheterization procedures in patients with Pulmonary hypertension in experienced centers.
- Temporal trends and drug exposures in Pulmonary hypertension: an American experience.
- Efficacy and safety of sildenafil added to treprostinil in Pulmonary hypertension.
- Outcome after cardioPulmonary resuscitation in patients with Pulmonary arterial hypertension.
- Comparison of survival in patients with Pulmonary hypertension associated with fenfluramine to patients with primary Pulmonary hypertension.
- Sitaxsentan therapy for Pulmonary arterial hypertension.
- Beraprost therapy for Pulmonary arterial hypertension.
- Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with Pulmonary arterial hypertension: open-label pilot study.
- Medical management of primary Pulmonary hypertension.
- Efficacy and safety of treprostinil: an epoprostenol analog for primary Pulmonary hypertension.
- Prognosis of Pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.
- Medical therapy for Pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.
- ''Raising the bar'' for the treatment of Pulmonary arterial hypertension.
- Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue Disease.
- ACCF/AHA 2009 expert consensus document on Pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents an...
- ACCF/AHA 2009 expert consensus document on Pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents a...
- Long-term ambrisentan therapy for the treatment of Pulmonary arterial hypertension.
- Long-term treatment with sildenafil citrate in Pulmonary arterial hypertension: the SUPER-2 study.
- Ambrisentan for the treatment of Pulmonary arterial hypertension: results of the ambrisentan in Pulmonary arterial hypertension, randomized, double-blind, placebo-cont...
- The Pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated ...
Schools
Northwestern University The Feinberg School Of Medicine
University Of Michigan
Northwestern University
Procedures Preformed
- Ablation for Treatment of Cardiac Arrhythmias
- Automatic Implantable Cardioverter Defibrillator (ICD) Implantation
- Cardiac Catheterization (incl. Coronary Angiography)
- Cardiac Imaging
- View All
Conditions Treated
- Angina and Acute Coronary Syndrome
- Aortic Aneurysm
- Aortic Valve Disease
- Arrhythmias (incl. Atrial Fibrillation)
- View All
Doctors Specialties
- Cardiology
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACC)
Education
-
McGaw Medical Center of Northwestern University -
University of Michigan Hospitals and Health Centers -
Northwestern University Feinberg School of Medicine
Hospital
-
University of Michigan Hospitals and Health Centers
Drug Facts
| NPI NUMBER | 1205912268 | |
| NPPES Provider LastName | MCLAUGHLIN | |
| NPPES Provider FirstName | VALLERIE | |
| NPPES Provider ZIPCode | 481095644 | |
| NPPES Provider State | MI | |
| Specialty Description | Cardiology | |
| Total Claim Count | 3170.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 27.0 | |
| Percent Opioid Claims | 0.85 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1205912268 |
| Last Name Of The Provider | MCLAUGHLIN |
| First Name Of The Provider | VALLERIE |
| View All |
Similar Doctors
|
|
Dr. Udhay Krishnan, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Frank M. Bogun, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Todd M. Koelling, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark R. Benson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel T. Eitzman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward T. Kim, MD |
|
|
Dr. John L. Coatney, MD |
|
|
Dr. Maryse Palardy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael J. Howe, MD |
|
|
Dr. Ashley G. Funk, MD
This Doctor is OpenDoctor Recommended.
|